Gestational Diabetes Mellitus (GDM) is a significant health concern, affecting up to 14% of pregnancies worldwide. It not only poses immediate risks to the mother and fetus but also increases the long-term risk of type 2 diabetes and cardiovascular diseases. Hence, optimizing GDM management is crucial.
Early detection and diagnosis of GDM can significantly improve pregnancy outcomes. Universal screening for GDM at 24-28 weeks of gestation using oral glucose tolerance test is recommended. For high-risk women, early screening in the first trimester should be considered.
First-line management of GDM involves lifestyle modifications. A balanced diet rich in fiber and low in simple sugars, along with moderate-intensity exercise for at least 30 minutes a day, can help control blood glucose levels. Regular self-monitoring of blood glucose is also essential.
If lifestyle modifications are insufficient, pharmacological interventions may be required. Insulin therapy is the gold standard for GDM management. However, oral hypoglycemic agents like metformin and glyburide are gaining acceptance due to their convenience and cost-effectiveness.
Postpartum follow-up is vital as GDM increases the risk of developing type 2 diabetes later in life. An oral glucose tolerance test should be performed at 6-12 weeks postpartum. Thereafter, regular screening for diabetes is recommended.
Optimal management of GDM requires a multifaceted approach, including early detection, lifestyle modifications, pharmacological interventions, and postpartum follow-up. By adhering to these strategies, healthcare professionals can significantly improve maternal and fetal outcomes while reducing the long-term risk of type 2 diabetes and cardiovascular diseases.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation